⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
Securities Lawsuit Alert: Erasca, Inc. (ERAS) - Contact Levi & Korsinsky Before August 10, 2026
accessnewswire.com
ERAS
RVMD
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com
ERAS
RVMD
ERAS ALERT: Securities Fraud Class Action Launched Against Erasca, Inc. - August 10, 2026 Deadline
accessnewswire.com
ERAS
RVMD
Investor Alert: Deadline Approaching to Join Erasca, Inc. (ERAS) Class Action – Contact Levi & Korsinsky
accessnewswire.com
ERAS
RVMD
Investors Urged to Contact Levi & Korsinsky for Information Before August 10, 2026 - Erasca, Inc. (ERAS)
accessnewswire.com
ERAS
RVMD
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
globenewswire.com
RVMD
Contact Levi & Korsinsky by August 10, 2026 to Join Class Action Against Erasca, Inc. (ERAS)
accessnewswire.com
ERAS
RVMD
Join Class Action to Recover Losses from Erasca, Inc. (ERAS) - Contact Levi & Korsinsky Before August 10, 2026
accessnewswire.com
ERAS
RVMD
Join Class Action to Recover Losses from Erasca, Inc. (ERAS) - Contact Levi & Korsinsky Before August 10, 2026
accessnewswire.com
ERAS
RVMD
Recover Investment Losses: Class Action Initiated Against Erasca, Inc. (ERAS)
accessnewswire.com
ERAS
RVMD